{site_meta && site_meta.display_name} Logo

Reportable

Cut through the daily deluge of information from news, social media and scientific literature to better communicate to your audiences, monitor and measure your business reputation and keep a close eye on your competition.

RSS Feed for Reportable

BioMed X launches Women’s Health R&D Accelerator in Heidelberg

October 14, 2025Heidelberg, Germany, October 14, 2025 – BioMed X today announced the launch of XFem Labs, a new Women’s Health R&D Accelerator in Heidelberg. The purpose of this initiative, which is supported by the Gates Foundation, is to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.


Lifordi Immunotherapeutics to Present New Preclinical Data on Antibody Drug Conjugate LFD-200 Demonstrating Selective and Sustained Delivery of Glucocorticoid Payload to Immune Tissues Without Evidence of Toxicity

October 10, 2025BURLINGTON, MA – October 10, 2025 -- Lifordi Immunotherapeutics, Inc. , a biotech company developing antibody drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, will present additional preclinical data on its lead candidate LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells.


PR Club of New England Expands for 2025-2026 Season

October 1, 2025Boston, MA: October, 1, 2025 – The PR Club of New England, the region’s leading communications trade organization, today announced its new and expanded board of directors and strategic vision for the 2025-2026 term. Led by returning president Kaitlynn Cooney, the PR Club is committed to honoring its 77-year historic legacy, while setting the organization up for long-term success through educational programming, professional networking events, and membership growth.


Tevard Biosciences Presents Data Showing Compelling Full-Length Protein Rescue with tRNA-based Treatment for Duchenne Muscular Dystrophy and Dilated Cardiomyopathy at the 2025 FEBS Special Meeting

September 29, 2025Boston, MA - September 29, 2025 - Tevard Biosciences, Inc. , a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the presentation of new preclinical data showing potent restoration of full-length functional proteins in models of Duchenne muscular dystrophy (DMD) and dilated cardiomyopathy caused by titin truncations (DCM-TTNtv).


UGI to Begin Upgrades in Camp Hill Next Week

September 26, 2025FOR IMMEDIATE RELEASE Release Date: September 26, 2025 UGI Utilities, Inc. is scheduled to begin a natural gas main replacement project in Camp Hill on Wednesday, October 1.